BIX0.F BIOINVENT INTERN. SK 2

Healthcare Biotechnology Frankfurt Exchange
0.2705 EUR
Close of Nov 11, 2026
0.2130 3.21
Market cap
EUR 17.8M
P/E
-
P/B
0.94x
ROE
-239.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BIX0.F undervalued?

Graham number

The Graham number of BIOINVENT INTERN. SK 2 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BIOINVENT INTERN. SK 2 fundamental analysis

No fundamental analysis for BIOINVENT INTERN. SK 2 yet.

BIOINVENT INTERN. SK 2 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BIOINVENT INTERN. SK 2

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tu…

Full company profile